Source:http://linkedlifedata.com/resource/pubmed/id/19405813
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2009-5-7
|
pubmed:abstractText |
Myostatin is a member of the transformating growth factor-beta (TGF-beta) superfamily of proteins and is produced almost exclusively in skeletal muscle tissue, where it is secreted and circulates as a serum protein. Myostatin acts as a negative regulator of muscle mass through the canonical SMAD2/3/4 signaling pathway. Naturally occurring myostatin mutants exhibit a 'double muscling' phenotype in which muscle mass is dramatically increased as a result of both hypertrophy and hyperplasia. Myostatin is naturally inhibited by its own propeptide; therefore, we assessed the impact of adeno-associated virus-8 (AAV8) myostatin propeptide vectors when systemically introduced in MF-1 mice. We noted a significant systemic increase in muscle mass in both slow and fast muscle phenotypes, with no evidence of hyperplasia; however, the nuclei-to- cytoplasm ratio in all myofiber types was significantly reduced. An increase in muscle mass in slow (soleus) muscle led to an increase in force output; however, an increase in fast (extensor digitorum longus [EDL]) muscle mass did not increase force output. These results suggest that the use of gene therapeutic regimens of myostatin inhibition for age-related or disease-related muscle loss may have muscle-specific effects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1557-8577
|
pubmed:author |
pubmed-author:BickhamDaleD,
pubmed-author:DicksonGeorgeG,
pubmed-author:FosterHelenH,
pubmed-author:FosterKeithK,
pubmed-author:GrahamIan RIR,
pubmed-author:KawarSusannah LSL,
pubmed-author:LuberitzBB,
pubmed-author:OttoAnthonyA,
pubmed-author:PatelKetanK,
pubmed-author:TrolletCapucineC,
pubmed-author:WalshFrank SFS,
pubmed-author:YaworskyPaul JPJ
|
pubmed:issnType |
Electronic
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
85-94
|
pubmed:meshHeading |
pubmed-meshheading:19405813-Animals,
pubmed-meshheading:19405813-Biomechanics,
pubmed-meshheading:19405813-Body Weight,
pubmed-meshheading:19405813-Cell Nucleus,
pubmed-meshheading:19405813-Dependovirus,
pubmed-meshheading:19405813-Gene Transfer Techniques,
pubmed-meshheading:19405813-Hyperplasia,
pubmed-meshheading:19405813-Hypertrophy,
pubmed-meshheading:19405813-Injections, Intravenous,
pubmed-meshheading:19405813-Mice,
pubmed-meshheading:19405813-Muscle Fibers, Fast-Twitch,
pubmed-meshheading:19405813-Muscle Fibers, Slow-Twitch,
pubmed-meshheading:19405813-Myostatin,
pubmed-meshheading:19405813-Organ Size,
pubmed-meshheading:19405813-Peptides,
pubmed-meshheading:19405813-Protein Precursors,
pubmed-meshheading:19405813-Satellite Cells, Skeletal Muscle
|
pubmed:year |
2009
|
pubmed:articleTitle |
Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle.
|
pubmed:affiliation |
SWAN Institute of Biomedical and Life Sciences, School of Biological Sciences, Royal Holloway-University of London, Egham, UK.
|
pubmed:publicationType |
Journal Article
|